Management of latent Mycobacterium tuberculosis infection: WHO guidelines for low tuberculosis burden countries

…, J Denholm, G De Vries, D Falzon… - European …, 2015 - Eur Respiratory Soc
Latent tuberculosis infection (LTBI) is characterised by the presence of immune responses
to previously acquired Mycobacterium tuberculosis infection without clinical evidence of …

Towards tuberculosis elimination: an action framework for low-incidence countries

…, D Falzon, MA Gaudreau, D Goletti… - European …, 2015 - Eur Respiratory Soc
This paper describes an action framework for countries with low tuberculosis (TB) incidence
(<100 TB cases per million population) that are striving for TB elimination. The framework …

Epidemiology of antituberculosis drug resistance 2002–07: an updated analysis of the Global Project on Anti-Tuberculosis Drug Resistance Surveillance

A Wright, M Zignol, A Van Deun, D Falzon, SR Gerdes… - The Lancet, 2009 - thelancet.com
Background The Global Project on Anti-Tuberculosis Drug Resistance has been gathering
data since 1994. This study provides the latest data on the extent of drug resistance worldwide…

WHO's new end TB strategy

…, E Jaramillo, C Lienhardt, HM Dias, D Falzon… - The Lancet, 2015 - thelancet.com
On May 19, 2014, the 67th World Health Assembly (WHA) adopted WHO’s “Global strategy
and targets for tuberculosis prevention, care and control after 2015”. 1 This post-2015 global …

WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update

D Falzon, E Jaramillo, HJ Schünemann, M Arentz… - 2011 - Eur Respiratory Soc
… The lead authors of this article were D. Falzon, E. Jaramillo and HJ Schünemann. GB
Migliori contributed to the adaptation of the text from the guidelines and the initial review of the …

[HTML][HTML] Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

…, K DeRiemer, NH Dung, D Enarson, D Falzon… - 2012 - journals.plos.org
Background Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic,
expensive, and has generally poor outcomes. We undertook an individual patient data meta-…

Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes

D Falzon, N Gandhi, GB Migliori… - European …, 2013 - Eur Respiratory Soc
A meta-analysis for response to treatment was undertaken using individual data of multidrug-resistant
tuberculosis (MDR-TB) (resistance to isoniazid and rifampicin) patients from 26 …

Rapid molecular TB diagnosis: evidence, policy making and global implementation of Xpert MTB/RIF

…, C Gilpin, J de Dieu Iragena, D Falzon… - European …, 2013 - Eur Respiratory Soc
If tuberculosis (TB) is to be eliminated as a global health problem in the foreseeable future,
improved detection of patients, earlier diagnosis and timely identification of rifampicin …

World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update

D Falzon, HJ Schünemann, E Harausz… - European …, 2017 - Eur Respiratory Soc
Antimicrobial resistance is a major global concern. Tuberculosis (TB) strains resistant to
rifampicin and other TB medicines challenge patient survival and public health. The World …

[HTML][HTML] Drug-resistant tuberculosis: time for visionary political leadership

I Abubakar, M Zignol, D Falzon… - The Lancet infectious …, 2013 - thelancet.com
Two decades ago, WHO declared tuberculosis a global emergency, and invested in the highly
cost-effective directly observed treatment short-course programme to control the epidemic…